Science
In the rush to develop a vaccine or treatment for Covid-19, drug companies are fast-tracking clinical trials. But those trials have a major diversity problem. Participants in major drug trials range from 70 percent to 89 percent white. This is a big problem, considering it’s a disease that disproportionately affects people of color. Kristen V. Brown reports that failing to account for minority groups could potentially impact how well a drug eventually works for those that the virus has harmed the most.
See omnystudio.com/listener for privacy information.
More Episodes
The Story Behind the Six Foot Rule
2020-07-15
2020-07-15
New Ways to Catch the Virus
2020-07-13
2020-07-13
Excruciating Choices For Schools
2020-07-10
2020-07-10
Virus Treatment Is Changing
2020-07-08
2020-07-08
A Divided America Feeds the Crisis
2020-07-03
2020-07-03
Why Deaths Seem to Drop as Cases Rise
2020-07-01
2020-07-01
Learning to Love Big Pharma
2020-06-29
2020-06-29
Keeping Elderly Patients Safe
2020-06-26
2020-06-26
What Happened in Houston
2020-06-25
2020-06-25
These Gadgets Know You're Sick Before You Do
2020-06-24
2020-06-24
The Next Two Years of the Virus
2020-06-23
2020-06-23
History's Lessons for Our Post-Virus Future
2020-06-22
2020-06-22
How to Spot a Fake Mask
2020-06-19
2020-06-19
The New Superbug Threat
2020-06-18
2020-06-18
Should You Take an Antibody Test?
2020-06-17
2020-06-17
The Virus Explodes in Latin America
2020-06-16
2020-06-16
Welcome to the Second Wave
2020-06-15
2020-06-15
The Effect of Quarantine on Kids
2020-06-12
2020-06-12
Get this podcast on your
phone, FREE
